King Pharmaceuticals, based in Bristol, Tennessee, will purchase
Avinza (morphine sulphate extended release) from Ligand Pharmaceuticals,
Inc. (San Diego). King will pay $265 million for the rights to the
product in the United States, its territories, and Canada, and will
assume product-related liability obligations.
COPYRIGHT 2006 Medicom International,
Inc. Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
Copyright 2006, Gale Group. All rights
reserved. Gale Group is a Thomson Corporation Company.
NOTE: All illustrations and photos have been removed from this article.
Copyright ©
Entrepreneur.com, Inc. All rights reserved.
Privacy Policy